Regencell Bioscience Holdings Ltd
RGC
Company Profile
Business description
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems.
Contact
29 Leighton Road
9/F Chinachem Leighton Plaza
Causeway Bay
Hong Kong
HKGT: +852 21550823
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
30 June 2026
Employees
12
Stocks News & Analysis
stocks
Strong result for ASX insurer but not the new norm
Stellar first half profits but increasing competition will lower future rate increases.
stocks
Eli Lilly earnings: Weak Orforglipron obesity data weighs down a strong quarter
With today’s share drop, we think Lilly stock looks fairly valued.
stocks
Solid 2025 for A-REIT but development activity will weigh on 2026
Positive news for income investors as yield exceeds 5%.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,117.60 | 41.00 | 0.45% |
| CAC 40 | 7,739.62 | 3.38 | -0.04% |
| DAX 40 | 24,113.27 | 49.59 | -0.21% |
| Dow JONES (US) | 44,175.61 | 206.97 | 0.47% |
| FTSE 100 | 9,131.02 | 35.29 | 0.39% |
| HKSE | 24,888.29 | 29.47 | 0.12% |
| NASDAQ | 21,450.02 | 207.32 | 0.98% |
| Nikkei 225 | 41,820.48 | 761.33 | 1.85% |
| NZX 50 Index | 12,911.86 | 67.23 | 0.52% |
| S&P 500 | 6,389.45 | 49.45 | 0.78% |
| S&P/ASX 200 | 8,844.80 | 37.70 | 0.43% |
| SSE Composite Index | 3,647.55 | 12.42 | 0.34% |